文献速递慢性肾脏病肾小球疾病

FLOW试验:司美格鲁肽按CKD严重程度的安全性结局

Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.
PubMed 文献 · Kidney Int · 2026-10-20

FLOW试验预设二次分析,按基线eGFR分层评估2型糖尿病合并CKD患者使用司美格鲁肽的安全性。3533例受试者中,司美格鲁肽组严重不良事件报告率低于安慰剂组,因胃肠道不良事件停药率高于安慰剂,各eGFR亚组未发现非预期安全问题。

要点

  • 司美格鲁肽严重不良事件报告率低于安慰剂,各eGFR亚组一致。
  • 因胃肠道不良事件停药司美格鲁肽4.5%高于安慰剂1.1%。
  • 各eGFR亚组特别关注不良事件频率两组相似。

核心结论

  • 司美格鲁肽严重不良事件报告率低于安慰剂,各eGFR亚组未发现非预期安全问题。

研究设计与样本

  • FLOW为双盲随机安慰剂对照试验,预设二次安全性分析,共3533例2型糖尿病合并CKD患者。

主要发现

  • 司美格鲁肽组严重不良事件45.1%低于安慰剂50.4%(eGFR≥60亚组),56.4%低于60.4%(eGFR<30亚组)。
  • 因不良事件停药率随基线eGFR降低而升高,eGFR≥60亚组司美格鲁肽11.2% vs 安慰剂11.3%,eGFR<30亚组18.8% vs 18.7%。
  • 因胃肠道不良事件停药司美格鲁肽4.5%高于安慰剂1.1%,各eGFR亚组一致。
  • 特别关注不良事件频率两组各eGFR亚组相似。

临床怎么用

  • 在2型糖尿病合并CKD各eGFR水平使用司美格鲁肽时,严重不良事件风险不高于安慰剂。
  • 需关注胃肠道不良事件导致的停药,尤其低eGFR患者总体停药率更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: People with type 2 diabetes (T2D) and chronic kidney disease (CKD) often experience medication intolerance and side effects that worsen with lower estimated glomerular filtration rate (eGFR). This prespecified secondary analysis assessed the safety of semaglutide by baseline eGFR. METHODS: FLOW (NCT03819153) was a double-blind, randomized, placebo-controlled trial testing the efficacy of subcutaneous semaglutide 1.0 mg once-weekly on a primary kidney outcome (50% or more eGFR reduction, kidney failure, or death due to kidney or cardiovascular causes) in participants with T2D and CKD. Safety data were collected selectively and included serious adverse events (SAEs), AEs leading to treatment discontinuation, and prespecified AEs of special interest (AESIs). In this descriptive assessment, systematically collected safety data were reported numerically by baseline eGFR. RESULTS: Of 3533 participants, 1767 received semaglutide and 1766 received placebo. Fewer SAEs were reported with semaglutide than placebo across baseline eGFR subgroups (45.1% versus 50.4% in the 60 or more ml/min per 1.73 m2 subgroup, and 56.4% versus 60.4% in the under 30 ml/min per 1.73 m2 subgroup). SAEs related to infections and infestations; cardiac disorders; respiratory, thoracic and mediastinal disorders; and metabolism and nutrition disorders were generally less frequent with semaglutide than placebo, regardless of baseline eGFR. Treatment discontinuations due to AEs were higher with lower baseline eGFR across treatment groups (60 or more ml/min per 1.73 m2: semaglutide 11.2%, placebo 11.3%; under30 ml/min per 66 1.73 m2: semaglutide 18.8%, placebo 18.7%). Discontinuations specifically due to gastrointestinal AEs were reported more frequently with semaglutide (4.5%) than placebo (1.1%), regardless of baseline eGFR. Frequencies of AESI were similar between treatment groups across baseline eGFR subgroups. CONCLUSIONS: In this safety assessment, SAEs were reported less frequently with semaglutide than placebo, with corresponding patterns observed for treatment discontinuations and AESIs. No unexpected safety concerns were identified across the spectrum of eGFR represented in the FLOW trial.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Andersen MR, Arici M, et al. Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial. Kidney Int. 2026. PMID: 42901325. doi:10.1016/j.kint.2026.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。